DrugPatentWatch Database Preview
CAYSTON Drug Patent Profile
Email this page to a colleague
When do Cayston patents expire, and when can generic versions of Cayston launch?
Cayston is a drug marketed by Gilead and is included in one NDA. There are four patents protecting this drug.
This drug has fifty-six patent family members in twenty-one countries.
The generic ingredient in CAYSTON is aztreonam. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aztreonam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cayston
A generic version of CAYSTON was approved as aztreonam by FRESENIUS KABI USA on June 18th, 2010.
Summary for CAYSTON
| International Patents: | 56 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 31 |
| Clinical Trials: | 6 |
| Patent Applications: | 4,223 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CAYSTON |
| What excipients (inactive ingredients) are in CAYSTON? | CAYSTON excipients list |
| DailyMed Link: | CAYSTON at DailyMed |
Recent Clinical Trials for CAYSTON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Dundee | Phase 2 |
| Gilead Sciences | Phase 2 |
| UCSF Benioff Children's Hospital Oakland | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for CAYSTON
US Patents and Regulatory Information for CAYSTON
CAYSTON is protected by four US patents.
Patents protecting CAYSTON
Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Patent Number: ⤷ Try it Free
Patent Expiration: ⤷ Try it Free
Patented Use: IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAYSTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Try it Free | ⤷ Try it Free |
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Try it Free | ⤷ Try it Free |
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Try it Free | ⤷ Try it Free |
| Gilead | CAYSTON | aztreonam | FOR SOLUTION;INHALATION | 050814-001 | Feb 22, 2010 | ⤷ Try it Free | ⤷ Try it Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAYSTON
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2301524 | ⤷ Try it Free |
| Israel | 221036 | ⤷ Try it Free |
| Canada | 2708703 | ⤷ Try it Free |
| Cyprus | 1119753 | ⤷ Try it Free |
| Australia | 2004257632 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CAYSTON
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2158901 | 2018C/001 | Belgium | ⤷ Try it Free | PRODUCT NAME: CAYSTON - AZTREONAM; AUTHORISATION NUMBER AND DATE: EU/1/09/543/001 20090923 |
| 1353647 | 365 | Finland | ⤷ Try it Free | |
| 1353647 | 91851 | Luxembourg | ⤷ Try it Free | 91851, EXPIRES: 20240921 |
| 1353647 | 1190027-1 | Sweden | ⤷ Try it Free | MARKETING AUTHORIZATION NUMBER AND DATE OF GRANT/NOTIFICATION: EU/1/09/543/001, 2009-09-23; PERIOD OF VALIDITY (FROM - UNTIL): 2021-12-21 - 2024-09- 22 |
| 2158901 | 122018000042 | Germany | ⤷ Try it Free | PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
